Core Viewpoint - UBS maintains an optimistic outlook on the long-term potential of China's healthcare market, but due to a 64% increase in the pharmaceutical sector driven by licensing optimism, along with rising risks from potential U.S. executive orders and high valuations, the market focus is expected to shift back to organic revenue/profit growth [1] Company Ratings - The ratings for CSPC Pharmaceutical Group (01093) and Kelun Pharmaceutical (002422) have been downgraded to "Neutral" due to weak fundamentals [1] - The preferred stock in the industry has shifted from 3SBio (01530) to Hansoh Pharmaceutical (03692) because of its stable traditional business and innovative pipeline reserves [1] Long-term Pipeline Potential - The report indicates that the best performers in terms of long-term pipeline potential are Hengrui Medicine (600276) and Hansoh Pharmaceutical [1] Valuation and Market Focus - Chinese pharmaceutical stocks have a forward P/E ratio higher than the five-year average, but the rising risk of U.S. executive orders is shifting market focus back to organic growth [1] - CSPC and Kelun are expected to have the lowest compound annual growth rate (CAGR) in revenue from 2024 to 2034, at half the average rate of 13% for 3SBio, Hansoh, and Innovent Biologics [1] Company-Specific Challenges - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, increasing uncertainty due to high reliance on unconfirmed business development revenue [1] - Kelun Pharmaceutical faces weak demand and intense competition, which may lead to the lowest revenue growth among peers by 2025 [1]

Group 1 - UBS maintains a positive outlook on the long-term potential of China's healthcare market, but notes a 64% increase in the pharmaceutical sector this year due to optimistic sentiment from licensing agreements, alongside rising risks from potential U.S. executive orders and high valuations [1] - The focus is expected to shift back to organic revenue/profit growth due to weak fundamentals, leading to downgrades for CSPC Pharmaceutical Group and Kelun Pharmaceutical to "Neutral" [1] - UBS has changed its preferred stock in the industry from 3SBio to Hansoh Pharmaceutical, citing Hansoh's stable traditional business and innovative pipeline reserves [1] Group 2 - The report indicates that the forward P/E ratio of Chinese pharmaceutical stocks is above the five-year average, with rising risks from U.S. executive orders shifting market focus back to organic growth [1] - CSPC and Kelun are projected to have the lowest compound annual growth rate (CAGR) for revenue from 2024 to 2034, at half the average of 13% for peers like 3SBio, Hansoh, and Innovent Biologics [1] - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, increasing uncertainty due to high reliance on unconfirmed business development revenue [1] - Kelun faces weak demand and intense competition, which may result in the lowest revenue growth among peers by 2025 [1]

Core Viewpoint - The MSCI China Healthcare Index has increased by 74.0% year-to-date, outperforming the MSCI China Index by 37.3% [1] Group 1: Market Trends - The recovery in capital market financing and the increase in overseas trading scale for innovative drugs have led to a rebound in domestic innovative drug research and development demand [1] - The CXO industry is expected to see performance recovery in the second half of the year due to the impact of U.S. interest rate cuts [1] Group 2: Regulatory Impact - The anticipated increase in tariffs on innovative drugs by the U.S. is expected to have a limited impact on the CXO sector [1] - Many multinational pharmaceutical companies already have plans to establish factories in the U.S., which may mitigate potential negative effects [1] Group 3: Future Outlook - The ongoing upward momentum for innovative drugs is expected to primarily come from overseas partners driving clinical progress for authorized pipelines [1] - There is optimism regarding valuation recovery opportunities in consumer healthcare, with recommendations to buy stocks in companies such as 3SBio, Junshi Biosciences, WuXi AppTec, Genscript Biotech, China National Pharmaceutical Group, and Innovent Biologics [1]

Investment Rating - The industry investment rating is "Outperform" [1] Core Insights - The report highlights that the recent tariff announcement by the U.S. government is expected to have a minimal impact on the pharmaceutical sector, suggesting that the current market downturn presents a good opportunity to increase positions in innovative drugs [4][13] - The report emphasizes the ongoing adjustments in the innovative drug sector, indicating that the recent price corrections are largely complete, and recommends maintaining or increasing exposure to high-quality stocks with growth potential [7][17] - The report discusses the positive outlook for the medical device sector due to new procurement policies aimed at preventing price wars, which could benefit companies previously affected by valuation pressures [8][23] Summary by Sections Industry Overview - The closing index for the pharmaceutical sector is 8770.86, with a weekly high of 9323.49 and a low of 6764.34 [1] Market Performance - For the week of September 22-26, 2025, the A-share pharmaceutical sector fell by 2.2%, underperforming the CSI 300 index by 3.27 percentage points and the ChiNext index by 4.16 percentage points [6][14][32] - The report ranks the pharmaceutical sector 26th among 31 first-level sub-industries in terms of weekly performance [14] Innovative Drugs - The innovative drug sector is experiencing a correction, with a recommendation to focus on high-quality stocks with growth potential, including companies like Innovent Biologics and Hengrui Medicine [7][17] Medical Devices - The National Healthcare Security Administration's new procurement policies are expected to positively impact the medical device sector, particularly benefiting companies like Mindray and Aohua [8][23] CDMO and CRO Sectors - The report expresses optimism about the CDMO sector's recovery, driven by increasing overseas demand and the upcoming interest rate cuts in the U.S. [18] - The CRO sector is also expected to see improved performance as domestic innovative drug demand stabilizes [18][19] Research Services - The report indicates a potential turnaround in the research services sector, with a focus on companies with strong competitive advantages [21] Biologics - The report notes that the blood products sector is currently facing downward pressure, while the vaccine sector is struggling due to declining birth rates and market saturation [22] Medical Services - The report highlights the potential for growth in the medical services sector, particularly for companies expanding their market share through acquisitions [26][27] Traditional Chinese Medicine - The report suggests that companies involved in innovative research and those benefiting from procurement policies are likely to see growth [28] Pharmaceutical Commerce - The report anticipates increased concentration in the retail pharmacy sector, with leading companies expected to gain market share [30][31]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index down 1.35% and the S&P 500 up 0.59% year-to-date performance for the Hang Seng Index stands at 30.25% [1][2] - The Chinese stock market saw declines, particularly in the technology, healthcare, and consumer discretionary sectors, while essential consumer goods, energy, and financials experienced gains [3] Industry Insights - The Chinese pharmaceutical industry is witnessing a recovery in domestic innovation research and development demand, with the MSCI China Healthcare Index up 74.0% since early 2025, outperforming the MSCI China Index by 37.3% [4] - The demand for early-stage research is showing positive signs, supported by a resurgence in capital market financing and a favorable environment for biotech innovation [9] - The CXO industry is expected to see performance recovery in the second half of 2025 due to increased demand for early-stage research and development [4][9] Company Analysis - WuXi AppTec (药明康德) is maintaining a strong growth trajectory in its TIDES business, with plans to expand peptide production capacity significantly by the end of 2025 [8] - The company reported a 14.5% year-on-year increase in new orders for preclinical services in the first half of 2025, with a notable 19.9% increase from U.S. clients [9] - WuXi AppTec's management is confident in maintaining resilient profitability, with adjusted gross and net profit margins reaching historical highs of 44.5% and 30.4% respectively in the first half of 2025 [10]

Core Viewpoint - The announcement of a 100% tariff on all branded/patented drugs by Trump starting in October is expected to have limited impact on China's innovative drug industry chain, with no excessive concerns warranted [1] Group 1: Impact on Innovative Drugs - Most Chinese innovative drugs that are currently being exported have either established production capacity in the U.S. or have outsourced production to local CMO companies [1] - The majority of domestic innovative drugs are exported using a business development (BD) model, which mitigates the impact of the tariff [1] Group 2: Impact on CXO Sector - The export products in the CXO sector primarily consist of raw materials and biological raw liquids, which are not affected by the new tariff; the proportion of finished dosage forms exported is low [1] - The investment timeline for multinational corporations (MNCs) to build factories in China will take time, leading to limited direct impact on CXO orders in the short term [1] - Long-term policy changes may influence the pace of factory construction by MNCs [1] Group 3: Upcoming Catalysts - The ESMO conference will take place in mid to late October, with a focus on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] - The results of medical insurance negotiations and the first version of the commercial insurance innovative drug directory are expected to be announced in October-November [1] Group 4: Mid to Long-term Recommendations - Recommended stocks in the innovative drug sector include 3SBio (01530) and Eucure Biopharma-B (06996), which have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] - Companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered undervalued with clear long-term growth logic [2] - In the CXO sector, WuXi AppTec (02268) is highlighted as a leading player benefiting from high downstream demand and improving financing conditions [2]

Group 1 - The core viewpoint is that the new 100% tariff on all branded/patented drugs announced by Trump will have limited impact on China's innovative drug industry chain, and there is no need for excessive concern [1] - For innovative drugs, most products currently being exported are either produced in the U.S. or outsourced to U.S. CMO, and most domestic innovative drugs are exported using the BD model [1] - For CXO, the main export products are raw materials and herbal extracts, which are not affected by the new tariff; the proportion of finished drug exports is low, and the investment timeline for MNC clients to build factories will take time, leading to limited short-term impact on CXO orders [1] Group 2 - Mid to long-term recommendations include innovative drugs such as 3SBio (01530) and Eucure Biopharma-B (06996), which have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] - Other recommended companies include Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech, which are considered significantly undervalued with clear long-term growth logic [2] - For CXO, companies like WuXi AppTec (02268) are expected to benefit from high downstream demand and improving financing conditions [2]

Core Insights - The report highlights that the impact of Trump's 100% tariff on imported innovative drugs may be limited, suggesting a buying opportunity during market dips [1][2] - The Chinese innovative drug industry is expected to be minimally affected, as many companies have established production capabilities in the U.S. or have outsourced to local contract manufacturing organizations (CMOs) [2] - The report recommends focusing on specific companies with significant data releases at the upcoming ESMO conference and monitoring the results of healthcare negotiations [2] Industry Overview - The U.S. tariff policy primarily targets multinational pharmaceutical companies that rely on overseas production, pushing them to establish manufacturing facilities in the U.S. [2] - The impact on the CXO sector is expected to be limited in the short term, as the majority of exports consist of raw materials and biological drug solutions, with a low proportion of finished drug exports [2] - The report indicates that the overall influence of the tariff on the Chinese pharmaceutical supply chain is manageable, contrasting with previous more aggressive statements from the Trump administration [2] Investment Recommendations - The report identifies potential catalysts for the pharmaceutical sector in Q4 2025, including the ESMO conference and the upcoming healthcare negotiation results [2] - Recommended companies for investment include Innovent Biologics, Kelun-Biotech, and Rongchang Biologics, which are expected to have significant data releases [2] - Long-term investment opportunities are suggested in innovative drug companies like 3SBio and Eucure Biopharma, which are undervalued and have clear growth trajectories [2]

Group 1 - The core viewpoint of the reports indicates a recovery in domestic innovative drug research and development due to the resurgence of capital market financing and an increase in overseas transactions for innovative drugs [1] - The price of experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] - The CXO industry is expected to see performance recovery in the second half of 2025, driven by the continuous upward momentum of innovative drugs primarily from overseas partners pushing clinical pipelines [1] Group 2 - The report highlights a shift in global early-stage drug innovation research from Europe and the US to China, with multinational pharmaceutical companies increasingly sourcing innovative pipelines from Chinese biotech firms [1] - The proposed administrative order by the Trump administration to restrict the import of experimental treatments from China has sparked intense lobbying from two opposing groups: US biotech investors facing competition from Chinese innovations and large pharmaceutical companies benefiting from low-cost Chinese drugs [1] - The report emphasizes that the income and profit scale of large US pharmaceutical companies far exceed that of US biotech firms, suggesting they may have greater lobbying influence [1] Group 3 - The announcement of a 100% tariff on patented drugs unless pharmaceutical companies build factories in the US is expected to have a limited impact on the CXO sector, as many multinational companies already have plans to establish facilities in the US [2] - Significant investment plans have been announced by several multinational pharmaceutical companies for building factories and R&D facilities in the US, including Eli Lilly's $27 billion and Roche's $50 billion investments over the next five years [2] - The report notes that the construction of factories in the US typically takes over five years, and the progress may be affected by political and market uncertainties [2]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [2][30]. Core Insights - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index, which rose by 37.3% [1]. - There is a recovery in domestic demand for innovative drug research and development, driven by a resurgence in capital market financing and an increase in the scale of innovative drug transactions abroad [1]. - The price for experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1]. - The CXO industry is expected to see performance recovery in the second half of 2025 due to the impact of U.S. interest rate cuts [1]. Summary by Sections Industry Overview - The report anticipates that U.S.-China innovation cooperation will continue, despite differing opinions in the U.S. [4]. - The global pharmaceutical innovation pipeline is shifting from Western biotech firms to Chinese biotech companies [4]. - Major multinational pharmaceutical companies are investing significantly in U.S. facilities, which may mitigate the impact of proposed tariffs on innovative drugs [4]. Company Recommendations - The report recommends buying shares in the following companies: - 三生制药 (Sangfor) [2] - 巨子生物 (Giant Biotech) [2] - 药明合联 (WuXi AppTec) [2] - 固生堂 (Gushengtang) [2] - 中国生物制药 (China National Pharmaceutical) [2] - 信达生物 (Innovent Biologics) [2] Market Trends - The report highlights that the continuous rise in innovative drugs will primarily come from overseas partners pushing clinical pipelines that have been licensed [4]. - There is optimism regarding the valuation recovery opportunities in consumer healthcare [4].